Putnam Investments LLC lessened its holdings in Agenus Inc. (NASDAQ:AGEN – Get Rating) by 1.8% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 523,516 shares of the biotechnology company’s stock after selling 9,534 shares during the quarter. Putnam Investments LLC’s holdings in Agenus were worth $1,073,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus during the first quarter valued at $25,000. Commonwealth Equity Services LLC purchased a new position in Agenus in the third quarter valued at about $26,000. Leisure Capital Management purchased a new position in Agenus in the third quarter valued at about $26,000. Jump Financial LLC purchased a new position in Agenus in the third quarter valued at about $29,000. Finally, Metropolitan Life Insurance Co NY grew its stake in Agenus by 91.2% in the third quarter. Metropolitan Life Insurance Co NY now owns 17,084 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 8,150 shares in the last quarter. Institutional investors and hedge funds own 53.81% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have commented on AGEN shares. StockNews.com downgraded Agenus from a “hold” rating to a “sell” rating in a research note on Monday, November 14th. EF Hutton Acquisition Co. I initiated coverage on Agenus in a research note on Thursday, December 22nd. They issued a “buy” rating and a $8.30 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Agenus in a research report on Tuesday, February 28th. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.10.
Agenus Price Performance
Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN – Get Rating).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.